B MVMNT

B-MVMNT is a pre-clinical stage biotechnology company focused on developing novel therapeutics to combat muscle aging and longevity-related conditions. Founded by leading experts in the biology of aging, the company leverages proprietary insights into the DNA damage response (DDR) to identify targets that can preserve muscle mass and function. Their primary therapeutic focus is on sarcopenia, a condition characterized by the progressive loss of skeletal muscle mass and strength. By targeting the underlying molecular mechanisms of cellular aging, B-MVMNT aims to extend the healthy lifespan of patients suffering from age-related physical decline. The company operates primarily in a stealth or early-development mode, utilizing a platform approach to discover small molecule interventions.